Galapagos has committed to an open access policy that will provide online barrier-free access to company funded research published in peer-reviewed scientific journals. Galapagos is the third pharmaceutical company to introduce such a policy as part of its commitment to transparency.
Galapagos already publishes the results of clinical studies involving patients in peer-reviewed medical and scientific journals, regardless of their outcome. But in many cases the full article may not be freely available as it sits behind a subscription or fee paywall. This creates a barrier for some audiences who cannot read our research findings. Galapagos believes its research should be freely accessible once published.
Galapagos is announcing this commitment during International Open Access Week (19th to 25th October, 2020; see http://www.openaccessweek.org/) which aims to promote scientific openness as a powerful tool for building more equitable systems of sharing knowledge.
At Galapagos our aim is to contribute to society through the discovery of breakthrough therapies for diseases with a large unmet medical need. From November 1st 2020, our open access publication policy will allow everyone, including clinicians, healthcare professionals, patients and the wider public to read our scientific research free of charge when first published in peer-reviewed journals.